Outcome based on day-22 bone marrow and day-8 blood MRD results
| MRD . | 3-year EFS . | P value . | 3-year OS . | P value . |
|---|---|---|---|---|
| Bone marrow–positive (n = 93) | ||||
| Blood-positive (n = 66) | 31.5% ± 5.9% | <.01 | 46.5% ± 6.4% | .01 |
| Blood-negative (n = 27) | 63.0% ± 9.3% | 77.0% ± 8.3% | ||
| Bone marrow–negative (n = 133) | ||||
| Blood-positive (n = 29) | 68.1% ± 8.8% | NS | 82.1% ± 7.3% | NS |
| Blood-negative (n = 104) | 66.2% ± 4.7% | 81.0% ± 3.9% |
| MRD . | 3-year EFS . | P value . | 3-year OS . | P value . |
|---|---|---|---|---|
| Bone marrow–positive (n = 93) | ||||
| Blood-positive (n = 66) | 31.5% ± 5.9% | <.01 | 46.5% ± 6.4% | .01 |
| Blood-negative (n = 27) | 63.0% ± 9.3% | 77.0% ± 8.3% | ||
| Bone marrow–negative (n = 133) | ||||
| Blood-positive (n = 29) | 68.1% ± 8.8% | NS | 82.1% ± 7.3% | NS |
| Blood-negative (n = 104) | 66.2% ± 4.7% | 81.0% ± 3.9% |
EFS, event-free survival; NS, not significant; OS, overall survival.